The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $113.78

Today's change+1.06 +0.94%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $113.78

Today's change+1.06 +0.94%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Jazz Pharmaceuticals PLC up (U.S.)$1.06

Jazz Pharmaceuticals PLC closed up Friday by (U.S.)$1.06 or 0.94% to (U.S.)$113.78. Over the last five days, shares have lost 6.56% and sit 4.87% above their 52-week low. This security has underperformed the S&P 500 by 19.40% during the last year.

Key company metrics

  • Open(U.S.) $113.05
  • Previous close(U.S.) $112.72
  • High(U.S.) $115.75
  • Low(U.S.) $109.44
  • Bid / Ask-- / --
  • YTD % change-19.05%
  • Volume592,017
  • Average volume (10-day)686,300
  • Average volume (1-month)684,714
  • Average volume (3-month)696,166
  • 52-week range(U.S.) $108.50 to (U.S.) $194.73
  • Beta0.71
  • Trailing P/E22.56×
  • P/E 1 year forward11.83×
  • Forward PEG0.66×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $5.04
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+25.03%

Based on its net profit margin of 25.03%, Jazz Pharmaceuticals PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue341334309328
Total other revenue--------
Total revenue341334309328
Gross profit312312281299
Total cost of revenue28222829
Total operating expense209197193198
Selling / general / administrative104107112104
Research & development51282725
Depreciation / amortization26242532
Interest expense (income), net operating--------
Unusual expense (income)01719
Other operating expenses, total--------
Operating income132136117130
Interest income (expense), net non-operating-13-16-16-17
Gain (loss) on sale of assets--------
Other--------
Income before tax118119103115
Income after tax88887182
Income tax, total30313234
Net income88887182
Total adjustments to net income--------
Net income before extra. items88887182
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items88887182
Inc. avail. to common incl. extra. items88887182
Diluted net income88887182
Dilution adjustment--------
Diluted weighted average shares63636372
Diluted EPS excluding extraordinary itemsvalue per share1.391.401.121.13
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.391.591.131.29